Drug Profile
Research programme: Parkinson's disease therapies - Wyeth
Latest Information Update: 19 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 19 Sep 2011 No development reported for Parkinson's disease in USA (unspecified route)
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 19 Nov 2008 Early research in Parkinson's disease in USA (unspecified route)